The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Brolucizumab is a follow-up to Novartis’ blockbuster AMD therapy Lucentis (ranibizumab), which has been competing toe-to-toe in the AMD market with Eylea for several years. Novartis reported ...

Diabetic Macular Edema MarketThe global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

boosted by strong demand for a new formulation of its blockbuster eye drug Eylea. The company also announced a new quarterly cash dividend and boosted its share buyback program by $3 billion to ...

As the company faces increasing competition for its flagship product Eylea, it continues to leverage its strong research and development capabilities to expand its pipeline and explore new growth ...

A higher-dose formulation of Eylea saw U.S. sales more than double Regeneron Pharmaceuticals Inc.'s stock rose 3% early Tuesday, after the company posted better-than-expected fourth-quarter ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye disease drug Eylea HD during a conference call on Tuesday, the next ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...